The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy

Iñaki Lete¹ and José Allué²
¹Clinical Management Unit of Obstetrics and Gynecology, Hospital Universitario Araba, Vitoria, Spain. ²Plant Physiology Laboratory, Faculty of Biosciences, Universitat Autònoma de Barcelona, Bellatera, Spain.

ABSTRACT: The rhizomes of Zingiber officinale (ginger) have been used since ancient times as a traditional remedy for gastrointestinal complaints. The most active ingredients in ginger are the pungent principles, particularly gingerols and shogaols. Various preclinical and clinical studies have evaluated ginger as an effective and safe treatment for nausea and vomiting in the context of pregnancy and as an adjuvant treatment for chemotherapy-induced nausea and vomiting. Here, we provide an update and analysis of ginger use for the prevention of nausea and vomiting, with a focus on the types and presentations of ginger available. We also examine the pharmacokinetic properties of ginger and highlight the type and posology of ginger and its metabolites.

KEYWORDS: ginger, nausea and vomiting, pregnancy, chemotherapy

Introduction

Ginger (Zingiber officinale Roscoe) is a perennial herb belonging to the family Zingiberaceae, primarily grown in Asia and tropical regions, and is one of the most important and widely consumed herbs worldwide. Cultivated for its edible underground stem (rhizome), ginger has been used since antiquity both as a spice and as a herbal medicine to treat a variety of primarily gastrointestinal ailments, such as nausea, vomiting (emesis), diarrhea, and dyspepsia, and also diverse ailments, including arthritis, muscular aches, and fever.¹ This long and established history of medicinal use in humans has stimulated ongoing clinical trials to scientifically assess the effectiveness of ginger as an adjuvant therapy or as a complementary and alternative medicine (CAM) in a number of indications related to nausea and vomiting; the most studied of these include nausea and vomiting in pregnancy (NVP), chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting, and, to a lesser extent, motion sickness.² Ginger is considered as a safe herb for human consumption.³ Ginger appears on the US Food and Drug Administration generally recognized as safe list and is included in the pharmacopoeias of many Western countries. The British Herbal Compendium lists ginger as a remedy for vomiting with pregnancy along with other indications.⁴ Indeed, ginger capsules have been available in UK for more than 40 years as a remedy for motion sickness and as a carminative. In 2012, the European Medicines Agency published an assessment report from the committee of herbal medicinal products describing the use of ginger in the prevention of nausea and vomiting, concluding that plausible clinical evidence exists for the beneficial effects of dry powdered rhizome on a number of conditions related to nausea and vomiting.⁵ This review summarizes the development of ginger as an antiemetic for NVP and CINV and will also focus more on a critical appraisal of the different preparations and presentations of ginger available for patients and the posology used.

Ginger Chemistry and Pharmacological Effects

The rhizome of ginger contains a wide variety of biologically active secondary metabolites. The rhizome comprises 1%–4% of volatile oils and an oleoresin.⁶ The distinctive odor and flavor of ginger are due to these volatile oils and also nonvolatile phenolic compounds, which have pungent properties.⁷ The volatile (steam extracted) oils consist mainly of sesquiterpene hydrocarbons, predominantly zingiberol, which gives rise to the characteristic aroma of ginger. The nonvolatile phenolic phytochemicals of ginger consist of gingerols, shogaols, paradols, and zingerone, and more than 30 gingerol-related compounds can be fractionated from crude ginger.⁸ Gingerols correspond to a series of chemical homologs differentiated by the length of their unbranched alkyl chains (n6–n12). Of all the gingerols, 6-gingerol is the most abundant and well-investigated ginger phytochemical.⁹
The major pharmacological activity of ginger appears to be attributed to gingerols and shogaols, which are the dehydrated products of gingerols. Consequently, gingerols are the major components in the fresh ginger rhizome, whereas shogaols, especially 6-shogaol, are the most abundant polyphenolic constituents of dried ginger.7

In relation to its antiemetic properties, ginger (and its constituents) acts peripherally, within the gastrointestinal tract, by increasing the gastric tone and motility due to anticholinergic and antiserotonergic actions.9,10 It is also reported to increase gastric emptying.11 This combination of functions explains the widely accepted ability of ginger to relieve symptoms of functional gastrointestinal disorders, such as dyspepsia, abdominal pain, and nausea, which is often associated with decreased gastric motility. Although the exact mode of action of ginger in relation to its antiemetic properties is still being unraveled, three recent studies have investigated the action of ginger on serotonin (5-hydroxytryptamine, 5-HT3, and 5-HT4) and cholinergic (M3) receptor activities.12–14 Working on the evidence that emetogenic chemotherapeutic drugs increase 5-HT concentration and activate visceral vagal afferent nerve activity, Jin et al used patch-clamp methods to study the effects of ginger and its pungent constituents on 5-HT-evoked inward currents in rat nodose ganglia neurons. Results showed that 6-shogaol, 6-gingerol, and zingerone could inhibit the 5-HT response in a concentration-dependent manner, with 6-shogaol exhibiting the greatest potency.12 Furthermore, the inhibition of 5-HT activity occurred in a noncompetitive manner, validating the earlier work.10 Using a different methodological approach (calcium influx and radioligand-binding assays), Walstab et al.13 used heterologous expression to demonstrate, for the first time, the inhibitory effect of 6-shogaol and 6-gingerol on recombinant human 5-HT3 receptors and also native receptors from human gut enteric neurons. This inhibition was found to be noncompetitive since a 5-HT3 receptor antagonist, GR65630, was not displaced by the ginger extract. Interestingly, both studies posited that since binding of ginger to 5-HT receptors occurs at a site other than the orthosteric-binding site of competitive 5-HT antagonists, combination therapy with known pharmaceutical 5-HT antagonists might increase the antiemetic efficacy. Additionally, using a bioassay for contractile (M) 3 receptors (guinea pig ileum), Pertz et al.14 demonstrated that 6-, 8-, and 10-gingerol and 6-shogaol could slightly but significantly depress carbachol-induced contractions. Collectively, these studies provide molecular evidence that ginger antagonizes activation of (M) 3 and 5-HT3 receptors, thereby inhibiting afferent inputs to the central nervous system that are stimulated by specific neurotransmitters, such as serotonin, released from the gastrointestinal tract.

Ginger has also been studied extensively in vitro and in animal models of hypertension, oxidative stress, fungal infection, and cancer; consequently, ginger has been investigated in the treatment of many different disease states, including cancer, osteoarthritis, and diabetes. These are beyond the scope of this review but have been the subject of several recent reviews.15–17

Presentations of Ginger
Ginger is used in numerous forms, including fresh, dried, pickled, preserved, crystallized, candied, and powdered or ground. Presentations can include capsules, tablets, tinctures, teas, and liquid extracts. Evidently, the concentrations of active ingredients (gingerols and shogaols) will differ between the different preparations and the processing steps involved. Indeed, gingerols are thermally labile, and the extent of gingerol-to-shogaol conversion will likely impact significantly on the medicinal benefits since the two compounds vary in their bioavailability and pharmacological properties.18 A recent methodological analysis using high-performance liquid chromatography (HPLC) coupled to time-of-flight mass spectrometry demonstrated that dried ginger powder products contained the highest quantity of gingerol-related compounds (7–14 mg/g), followed by fresh ginger (2–2.8 mg/g) and powdered ginger tea products (<0.8 mg/g).19 Attempts to assess the efficacy of ginger in many clinical trials might have been conceivably weakened by the inconsistency in the form of ginger used (fresh or dried) and also the dosing regimen. Of the 12 studies reviewed in a recent meta-analysis on the use of ginger in NVP, various preparations were described, including ginger biscuits, ginger powder capsules, ginger essence capsules, ginger extract capsules, and ginger syrup in water.20 Also, the daily dosage varied from 600 to 2500 mg. Similarly, in a recent systematic review on the use of ginger in CINV, typical dosing regimens were 1–2 g of ginger.21 To obtain patient compliance, it would be necessary to formulate ginger into the dosage forms that are practical to use, while retaining the active components. In this respect, capsules are the common dosage form considered for many oral drugs and different methodologies exist for the preparation of active gingerols (and shogaols) in capsule form.22 In the above meta-analysis of NVP, 10 out of 12 studies used ginger in a capsule form and 7 out of 7 the studies reviewed for CINV used encapsulated ginger.20 Considering the dosage, there is a remarkable lack of information on the concentration of active ingredients in the various preparations used in clinical trials; none of the NVP studies reviewed above described any form of chemical analysis to quantify the concentration of active ingredients, and only 2 out of 7 CINV studies did so. This is obviously essential information as commercial preparations of ginger may have widely different concentrations of gingerols. In a study of dietary ginger root supplements, Schwertner et al used HPLC to measure the concentrations of active ingredients in locally purchased ginger capsules. Results ranged from 0.0 to 9.43 mg/g for 6-gingerol, 0.16 to 2.18 mg/g for 6-shogaol, 0.00 to 1.1 mg/g for 8-gingerol, and 0.00 to 1.40 mg/g for 10-gingerol, and somewhat worryingly, the suggested daily dose varied from 250 mg to nearly 5 g.23 The absence of standardized ginger
Use of ginger in the prevention of nausea and vomiting

constituents has also been highlighted in a recent study protocol to assess ginger in the setting of chemotherapy-induced nausea. In this study design, the authors have chosen to use a commercially prepared ginger extract capsule that has been standardized to contain 5% gingerols (referring to the total gingerol strength), which is equivalent to 15 mg of active ingredient per 300 mg ginger extract and is an amount utilized in some previous clinical trials.

In addition to differences in the quantity of ginger used between studies, the dosing intervals also vary between clinical trials. In this regard, two recent clinical studies have investigated the pharmacokinetics of different ginger preparations in humans. In the first study, healthy volunteers were given a single oral dose of ginger, ranging from 100 mg to 2 g, and the blood samples were periodically taken up to 72 hours. Results showed that no free gingerols or shogaols could be detected in the plasma; however, these analytes were readily detected as predominantly glucuronide and sulfate conjugates in serum, indicating that gingerols undergo oxidation of their phenolic side chain. Extending this analysis, the same authors developed a more sensitive technique and established that free forms of 10-gingerol and 6-shogaol, as well as glucuronide metabolites of 6-, 8-, and 10-gingerol and 6-shogaol could be identified one hour after oral dosing with 2 g of the ginger extract. Interestingly, the half-life of these compounds and their metabolites was determined to be between one and three hours in human plasma, and multiple dosing experiments established that no accumulation of metabolites occurred. Given these results, it may be prudent to extend the frequency of dosing, within the expectations of patient compliance.

Although there is no consensus agreement on the correct dosage of ginger, most clinical studies recommend a safe daily dose of 1000 mg, at least in the setting on NVP. Accordingly, 7 out of 12 studies described in the Viljoen et al. meta-analysis used this final amount, and a subgroup analysis in this report favored the lower daily dosage of <1500 mg for nausea relief. As a demonstration, Ding et al. calculated that 1000 mg is equivalent to one teaspoon (5 g) of freshly grated ginger extract, 2 mL of liquid ginger extract, four cups (237 mL each) of prepackaged ginger tea, two teaspoons of ginger syrup (10 mL), or two pieces of crystallized ginger (1 in³). The European Medicines Agency monograph summarized the following most often used dosages (through June 2010): NVP 500 mg three times daily for three to five days, postoperative nausea and vomiting 1000 mg for one hour before induction of anesthesia, and motion sickness 1000 mg for one hour before start of travel. The US Food and Drug Administration generally recognized as safe list states that up to 4 g of ginger can be consumed daily, although these amounts are generally not reached in studies. Indeed, the illustration by Ding et al. serves to apprise patients of the ease of exceeding the maximum daily dose subject to the type of ginger consumed. Interestingly, these regimens often consider the prophylactic use of ginger to delay acute emesis, presumably working in a manner associated with priming of receptors. Indeed, successful treatments for CINV have been proven to be those given before chemotherapy treatment starts.

Clinical Effectiveness of Ginger

As stated earlier, the most common and well-established use of ginger is undoubtedly its utilization in alleviating symptoms of nausea and vomiting. In this sense, it is perhaps appropriate to mention the differences between nausea and vomiting. Nausea is characterized by an uncomfortable sensation experienced in the throat and epigastrum that may or may not result in the expulsion of contents from the stomach, while vomiting is the involuntary, forceful expulsion of contents from the stomach. Nausea and vomiting can occur separately, although since vomiting is nearly always preceded by nausea, they are often considered components of a single entity. Nausea is a nonobservable phenomenon, while vomiting is objective, and the occurrence and the frequency of vomiting may be measured. In the clinical setting, various instruments are used to assess nausea and vomiting based on self-reporting. The INV-2 or Rhodes Index of Nausea, Vomiting, and Retching is an eight-item self-report questionnaire that measures nausea and vomiting as separate entities and is used frequently as an outcome measure in controlled studies. Another common tool to measure nausea is a visual analog scale (VAS) of 0–10 cm to score severity.

Nausea and vomiting in pregnancy. Nausea and vomiting affects a large proportion of women in early pregnancy. It is thought that up to 80% of women have NVP in some degree during the first trimester of pregnancy, and for the majority of women, symptoms typically resolve by 12–14 weeks gestation. Colloquially known as morning sickness, this term is clearly a misnomer because symptoms can occur at any time of the day. In a small percentage of pregnancies (0.2%–5%), persistent and excessive nausea and vomiting resulting in dehydration, electrolyte imbalance, and weight loss (termed Hyperemesis gravidarum) can occur and is a leading cause of hospital admissions during the first half of pregnancy. Evidently, this often debilitating condition can have a significant impact on the quality of a woman’s life, both personally and professionally, and can be emotionally traumatic. The exact cause of NVP remains unclear and probably depends on several factors. Among these, a commonly accepted etiology is ascribed to hormonal changes that occur during pregnancy, such as elevation of serum human chorionic gonadotrophin, estrogens, and also Helicobacter pylori infection.

Several medications are currently available for the treatment of NVP. Emesis can be treated with drugs known as antiemetics, most notably serotonin (5-HT3) receptor antagonists. However, many women are cautious of medicines for fear of harming the fetus, especially given that NVP usually occurs during the vulnerable period of embryonic organogenesis. Accordingly, the popularity of CAM, including nonpharmacological medicines and herbal extracts, has
grown considerably in recent years, and a high frequency of CAM use during pregnancy has been noted. A recent multinational study on the prevalence of herbal medicine use in pregnancy found that over 28% of participating women used herbals (2735/9459). Of the 134 different herbs used, ginger and cranberry accounted for the majority of herbals (23.5% and 22.7%, respectively), with valerian and raspberry being also popular choices.

The impact of the use of ginger as an antiemetic in NVP has been extensively investigated in clinical studies for at least 30 years. Because of the heterogeneity inherent in the study design and occasional problems with quality, not all randomized clinical trials can be incorporated into a meta-analysis. Nonetheless, two meta-analyses of randomized clinical trials (Level I evidence) have been published very recently. In the smaller of the two meta-analyses, six studies conducted from 1991 to 2009 fulfilled the inclusion criteria, and 508 subjects were randomly assigned to receive ginger (~1000 mg daily) or placebo. Predictably, these studies varied in the formulation and dosage of ginger: three studies administered 250 mg ginger capsules four times daily, one study used 350 mg ginger capsules four times daily, one study administered 250 mg ginger syrup four times daily, and one study administered 500 mg ginger powder in biscuit, five biscuits daily. Although the duration of study also varied (between four days and three weeks), using an end point of improvement of early NVP, the meta-analysis demonstrated that ginger was better than placebo in improving NVP when given at a dose of ~1000 mg/d for at least four days. The authors of the meta-analysis concluded that ginger was an effective nonpharmacological option for NVP and was better than placebo. In the second systematic review and meta-analysis, Viljoen et al. studied the efficacy of orally administered ginger as treatment for NVP in pregnant women at any stage of pregnancy and reviewed randomized studies from 1991 to 2011. From 302 records identified through database searching, 12 studies met the criteria established by the authors, involving 1278 pregnant women and included the six studies reviewed by Thomson et al. The six additional studies used ginger capsules of different dosages: 125 mg four times daily, 200 mg three times daily, 325 mg (×2) three times daily, and 500 mg two times or three times daily. Ginger versus placebo was assessed in 7 out of 12 studies. Individual results from all seven studies concluded that ginger was more effective than placebo in relieving the intensity of NVP in general; however, only three from the seven studies concluded that ginger was more effective in reducing the number of vomiting episodes (although there was a trend for improvement). In four studies assessing ginger versus vitamin B6 supplementation, a common first-line treatment for nausea, three studies reported no difference between the two groups, and one study showed that ginger significantly improved nausea and vomiting symptoms. Besides this meta-analysis, a recently published study also found no significant differences between the ginger group (47 patients treated with 250 mg ginger four times daily) and the vitamin B6 group (40 mg twice daily).

One study assessed the efficacy of ginger against the antihistaminic drug dimenhydrinate and found ginger to be just as effective, with fewer side effects. Lastly, one study used metoclopramide, a dopamine receptor antagonist, as comparator. The effects of ginger were not significantly different from those obtained to metoclopramide. In conclusion, Viljoen et al acknowledged the limited number of studies and low quality of evidence, but based on the evidence, ginger could be a possibly effective option for women with NVP, although large standardized trials are necessary. A brief description of the studies is given in Table 1.

**Chemotherapy-induced nausea and vomiting.** CINV is a major adverse effect of chemotherapy, and cancer patients’ rate of nausea is the most distressing side effect of chemotherapy. The risk of suffering CINV is dependent on the emetic potential of the chemotherapy. Some chemotherapeutic agents, including cyclophosphamide and cisplatin, can lead to an extremely high incidence of CINV, upward of 90%. Nonetheless, two meta-analyses of randomized clinical trials can be incorporated into a meta-analysis. Because of the heterogeneity inherent in the study, a common first-line treatment for nausea, three studies assessed in 7 out of 12 studies.

A prior study of CINV also standardized the ginger constituents used in the trial and the capsules contained a purified liquid extract of ginger root with concentrated 8.5 mg of combined gingerols, zingerone, and shogaol content (equivalent to 250 mg of ginger root). Results from mixed-model analyses showed that all concentrations of ginger significantly reduced the incidence of acute, but not delayed, nausea, with 0.5 and 1.0 g being the most effective. A prior study of CINV also standardized the ginger concentration to a combination of active ingredients. In this case, HPLC analysis was used to verify the concentrations, which were found to be 2.15% 6-gingerol, 0.72% 8-gingerol, 1.78% 10-gingerol, and 0.37% 6-shogaol. Participants (129) were randomized to receive 1 g (four capsules of 250 mg) of ginger daily, 2 g (eight capsules) of ginger daily, or matching placebo for three days together with an antiemetic (5-HT3 receptor antagonists and/or aprepitant, a neurokinin 1 receptor blocker), and the duration of intervention was three days postchemotherapy. Although well tolerated, ginger provided no additional benefit for reduction of the prevalence or severity.
of acute or delayed CINV when used as an adjuvant therapy. These two studies were included in a recent review of controlled clinical trials by Marx et al,21 who performed a systematic search of the literature until April 2012. From 27 records analyzed, seven studies fitted the inclusion criteria. The five additional studies used the following encapsulated ginger of different dosages: 250 mg four times daily,66,67 500 mg three times68 or four times69 daily, and 167 mg six times daily or 400 mg five times daily depending on patient weight.70 Of the five additional studies, one reported no additional benefit to standard emetic control,66 two reported some benefit,68,70 and two reported that ginger performed equally well as metoclopramide.67,69 Thus, from the seven trials analyzed, five reported favorable results, while results from the other two clinical trials were unfavorable. Similar to the conclusions in the study by Viljoen et al,20 Marx et al posited that the mixed results from the trials could perhaps be explained by the nonstandardized preparations of ginger used and inconsistencies in study methods and outcomes.

Safety Issues of Ginger
Adverse effects after ingestion of ginger are uncommon but can include mild gastrointestinal complications, such as pyrosis (heartburn or reflux)71 and eructation (belching).50 In a study of 27 healthy volunteers who were given a single oral dose of ginger (ranging from 100 mg to 2 g), minor gastrointestinal upsets were the major treatment associated toxicities.25 Despite previous studies indicating that ginger could interfere with platelet aggregation and cause excessive bleeding,72 in a randomized crossover study of 12 healthy volunteers taking 1.2 g of dried rhizome three times daily for two weeks, ginger did not affect platelet aggregation and had no effect on the pharmacokinetics or pharmacodynamics of a single 25 mg dose of warfarin taken on day 7.73 Of note, the meta-analysis of NVP by Viljoen et al also reviewed the safety of ginger as a secondary objective. The authors found that ginger did "[not] pose a risk for side-effects or adverse events during pregnancy.720

Aside from Level I evidence, safety of ginger in NVP has been studied in at least two Level II (nonrandomized or cohort) studies. In the first prospective study, the pregnancy outcome of 187 women from Toronto who were exposed to ginger during the first trimester of pregnancy was compared with women who had been exposed to nonteratogenic drugs that were not antiemetics.74 There were no statistically significant differences between the two groups in terms of live births,

Table 1. Brief description of the 13 studies reviewed on ginger for treating nausea and vomiting in pregnancy.

| STUDY                  | TREATMENT                        | COMPARATOR  | DURATION (DAYS) | MAIN FINDINGS                                      |
|------------------------|----------------------------------|-------------|-----------------|---------------------------------------------------|
| Fischer-Rasmussen, 1991 | 250 mg ginger powder capsules (4 × daily) | Placebo     | 4               | Ginger was significantly more effective than the placebo |
| Vutyavanich, 2001      | 250 mg ginger powder capsules (4 × daily) | Placebo     | 4               | Ginger was significantly more effective than the placebo |
| Keating, 2002          | 250 mg ginger syrup (4 × daily)    | Placebo     | 14              | Ginger was more effective than the placebo          |
| Sripathome, 2003       | 500 mg ginger powder capsules (3 × daily) | 10 mg vitamin B6 capsules (3 × daily) | 3 | Ginger and vitamin B6 were both significantly more effective for treating NVP |
| Willets, 2003          | 125 mg ginger extract capsules (4 × daily) | Placebo     | 4               | Ginger was more effective than placebo for reducing nausea. No differences in vomiting |
| Smith, 2004            | 350 mg ginger capsules (3 × daily)  | 25 mg vitamin B6 capsules (3 × daily) | 21 | Ginger was equivalent to vitamin B6 for reducing nausea |
| Chittumma, 2007        | 325 mg ginger capsules × 2 (3 × daily) | 12.5 mg vitamin B6 capsules × 2 (3 × daily) | 4 | Ginger was significantly more effective than vitamin B6 |
| Pongrjapaw, 2007       | 500 mg ginger powder capsules (2 × daily) | 50 mg dimenhydrinate capsules (2 × daily) | 7 | Ginger was as effective as dimenhydrinate |
| Ensiyeh and Sakineh, 2009 | 500 mg ginger powder capsules (2 × daily) | 20 mg vitamin B6 capsules (2 × daily) | 4 | Ginger was significantly more effective that vitamin B6 |
| Ozgoli, 2009           | 250 mg ginger powder capsules (4 × daily) | Placebo     | 4               | Ginger was significantly more effective than placebo |
| Basirat, 2009          | 500 mg ginger biscuits (5 × daily)  | Placebo     | 4               | Ginger was significantly more effective than placebo |
| Mohammadbeigi, 2011    | 200 mg ginger essence capsules (3 × daily) | a. Placebo | b. 10 mg Metoclopramide capsules (3 × daily) | 5 | Ginger was less effective than metoclopramide, but the difference was non-significant |
| Haji Seid Javadi, 2013 | 250 mg ginger capsules (4 × daily)  | 40 mg vitamin B6 capsules (2 × daily) | 4 | Ginger was equivalent to vitamin B6 for reducing nausea |

Use of ginger in the prevention of nausea and vomiting

INTEGRATIVE MEDICINE INSIGHTS 2016:11 | 15
spontaneous abortions, therapeutic abortions, birth weight, or gestational age. A more recent and larger population-based cohort study in Norway (68,522 women) found that the use of ginger during pregnancy (1020 women, 1.5%) was not associated with an increased risk of congenital malformations, stillbirth/perinatal birth, low birth weight, or preterm birth.\textsuperscript{75}

**Conclusion**

Ginger is an ancient herb used widely in history for its many natural medicinal properties and particularly as an antiemetic. The best available evidence demonstrates that ginger is an effective and inexpensive treatment for nausea and vomiting and is safe. Given the attainability of ginger preparations with known active ingredients, it would be interesting to perform preclinical studies to understand the efficacy of principal ginger constituents, including gingerols and shogaols. Dose-finding studies using varied standardized extracts should also be undertaken to accurately determine the effective dose and preparation of ginger. The results from these studies could be used to optimize the design of clinical trials to enhance the efficacy of ginger in nausea and vomiting.

**Acknowledgments**

The authors are grateful to Adamed Farma for the unrestricted grant that made this article possible and to Kenneth McCreath and Nature Publishing Group for the editorial support.

**Author Contributions**

Conceived the concept: IL, JA. Analyzed the data: IL, JA. Wrote the first draft of the manuscript: IL, JA. Contributed to the writing of the manuscript: IL, JA. Agreed with manuscript results and conclusions: IL, JA. Jointly developed the structure and arguments for the article: IL, JA. Made critical revisions and approved the final version: IL, JA. Both authors reviewed and approved the final manuscript.

**REFERENCES**

1. Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 2008;46(2):409–20.
2. Palatyi PL, Hasiadka R, Valder B, Arora R, Baliga MS. Ginger in the prevention of nausea and vomiting: a review. Crit Rev Food Sci Nutr. 2013;53(7):659–69.
3. Kaul PN, Yoshi BS. Alternative medicine: herbal drugs and their critical appraisal—part II. Prog Drug Res. 2004;57:1–75.
4. Bradley PR, ed. British Herbal Compendium Vol. 1: A Handbook of Scientific Information on Widely Used Plant Drugs. Bournemouth: British Herbal Medicine Association; 1992.
5. Committee on Herbal Medicinal Products: Assessment report on Zingiber officinale Roscoe, rhizome. European Medicines Agency EMA/HPIC/577856/2010, 2011.
6. Farnsworth RF, Fong HHS, Mahady GB. WHO Monographs on Selected Medicinal Plants. Volume 1. Geneva, Switzerland: WHO Publications; 1999. Rhizoma Zingiberis.
7. Govindarajan VS. Ginger-chemistry, technology and quality evaluation: part-I. Crit Rev Food Sci Nutr. 1982;17(1):1–96.
8. Jiang H, Solyom AM, Timmermann BN, Gang DR. Characterization of gingerol-related compounds in ginger rhizome (Zingiber officinale Rosc.) by high-performance liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(20):2957–64.
9. Shibata C, Sasaki I, Naino H, Ueno T, Marusono S. The herbal medicine Dai-Kenchu-Tou stimulates upper gut motility through cholinergic and 5-hydroxytryptamine 3 receptors in conscious dogs. Surgery. 1999;126(5):918–24.
10. Adelz-Aziz H, Wintek D, Ploh M, Verspohl EJ. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 2006;530(1–2):136–43.
11. Hu ML, Rayner CK, Wu KL, et al. Effect of ginger on gastric motility and symptoms of functional dyspepsia. World J Gastroenterol. 2011;17(1):105–10.
12. Jin Z, Lee G, Kim S, Park CS, Park YS, Jin YH. Ginger and its pungent constituents non-competitively inhibit serotonin currents on vasa deferentia neurons. Korean J Physiol Pharmacol. 2014;18(2):149–53.
13. Walzl J, Krüger D, Stark T, et al. Ginger and its pungent constituents non-competitively inhibit activation of human recombinant and native 5-HT3 receptors of enteric neurons. Neurogastroenterol Motil. 2013;25(5):439–47.
14. Pertz HH, Lehmann J, Roth-Ehrgang R, Ela S. Effects of ginger constituents on the gastrointestinal tract: role of cholinergic M3 and serotonergic 5-HT3 and 5-HT4 receptors. Planta Med. 2011;77(10):973–8.
15. Li Y, Tran VH, Duke CC, Roufogalis BD. Preventative and protective properties of Zingiber officinale (Ginger) in diabetes mellitus, diabetic complications and associated lipid and other metabolic disorders: a brief review. Evid Based Complement Alternat Med. 2012;2012:516870.
16. Poltronieri J, Becceneri AB, Puzer AM, et al. [6]-gingerol as a cancer chemopreventive agent: a review of its activity on different steps of the metastatic process. Mini Rev Med Chem. 2014;14(8):713–21.
17. Bartels EM, Folner VN, Bliddal H, et al. Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2015;23(13):1–21.
18. Baliga MS, Hasiadka R, Pereira MM, et al. Update on the chemopreventive effects of ginger and its phytochemicals. Crit Rev Food Sci Nutr. 2011;51(6):499–523.
19. Park JS, Jung MY. Development of high-performance liquid chromatography-time-of-flight mass spectrometry for the simultaneous characterization and quantitative analysis of gingerol-related compounds in ginger products. J Agric Food Chem. 2012;60(40):10015–26.
20. Viljoen E, Visser J, Koen N, Musiwaia A. A systemic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr J. 2014;13:20.
21. Marx WM, Teleni L, McCarthy AL, et al. Ginger (Zingiber officinale) and cancer chemotherapy-induced nausea and vomiting: a systematic literature review. Nutr Rev. 2013;71(4):245–54.
22. Tunsirikongkon A, Kraisit P, Seubsasana S, Harathar A, Sarisata N. Formulation development of herbal capsule containing oleosins of Zingiber officinale extract. Int J Pharm Sci. 2013;5(4):49–55.
23. Schwerterme HA, Klos DG, Pascoe JE. Variation in concentration and labeling of ginger root dietary supplements. Obstet Gynecol. 2006;107(6):1337–43.
24. Marx W, McCarthy AL, Ried K, et al. Can ginger ameliorate chemotherapy-induced nausea? Protocol of a randomized double blind, placebo-controlled trial. BMC Complement Altern Med. 2014;14:134.
25. Zick SM, Ruffin MT, Lee J, et al. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Can. 2009;17(5):563–72.
26. Yu Y, Zick S, Li X, Zou P, Wright B, Sun D. Examination of the pharmacokinetics of active ingredients of ginger in humans. JAPS J. 2011;13(3):417–26.
27. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting in pregnancy. Drugs. 2000;59(4):781–800.
28. Vutyanovitch T, Krasirian T, Ruaniri R. Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. Obstet Gynecol. 2001;97(4):577–82.
29. Ozgoli G, Golli M, Simbar M. Effects of ginger capsules on pregnancy, nausea, and vomiting, J Altern Complement Med. 2009;15(3):243–6.
30. Ding M, Leach M, Bradley H. The effectiveness and safety of ginger for pregnancy-induced nausea and vomiting: a systematic review. Women Birth. 2013;26(1):26–30.
31. Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007;101(3):143–50.
32. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg. 2006;102(6):1884–98.
33. Rhodes VA, McDaniel RW. Nausea, vomiting, and retching: complex problems in palliative care. CA Cancer J Clin. 2001;51(4):232–48.
34. Rhodes VA, McDaniel RW. The index of nausea, vomiting, and retching: a new format for the index of the index of nausea and vomiting. Oncol Nurs Forum. 1999;26(5):889–94.
35. Vellacott ID, Cooke EJ, James CF. Nausea and vomiting in early pregnancy. Int J Gynaecol Obstet. 1988;27(1):57–62.
36. Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: a prospective study of its frequency, intensity and patterns of change. Am J Obstet Gynecol. 2000;182(4):931–7.

Lete and Allué

INTEGRATIVE MEDICINE INSIGHTS 2016:11
37. Gadsby R, BARNIE-ADHEAD AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. Br J Gen Pract. 1993;43(371):245–8.

38. McCarthy FP, Luotojoki JE, Greene RA. Hyperemesis gravidarum: current perspectives. Int J Womens Health. 2014;7:19–25.

39. Lee NM, Saha S. Nausea and vomiting of pregnancy: Gastroenterol Clin North Am. 2011;40(3):309–34.

40. Davis M. Nausea and vomiting of pregnancy: an evidence-based review. J Perinat Neonatal Nurs. 2004;18(4):312–28.

41. Verberg MF, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum, a literature review. Hum Reprod Update. 2005;11(5):527–39.

42. Niemeijer MN, Grooten IJ, Vos N, et al. Diagnostic markers for Hyperemesis gravidarum: a systematic review and metaanalysis. Am J Obstet Gynecol. 2014;211(2):e1–15.

43. Koren G, Levichek Z. The teratogenicity of drugs for nausea and pregnancy: perceived versus true risk. Am J Obstet Gynecol. 2002;186(suppl 5):S248–52.

44. Matthews A, Haas DM, O’Mathúna DP, Dowswell T, Doyle M. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev. 2014;3:CD007575.

45. Hall HR, Jolly K. Women’s use of complementary and alternative medicines during pregnancy: a cross-sectional study. Midwifery. 2014;30(5):499–505.

46. Kennedy DA, Lupattelli A, Koren G, Norden H. Herbal medicine use in pregnancy: results of a multinational study. BMC Complement Altern Med. 2013;13:355.

47. Giasoca A, Morazzoni P, Bombardelli E, Riva A, Bianchi Porro G, Rondanelli M. Can nausea be treated with ginger extract? Eur Rev Med Pharmacol Sci. 2015;19(7):1291–6.

48. Thomson M, Corbin R, Leung L. Effects of ginger for nausea and vomiting in early pregnancy: a meta-analysis. J Am Board Fam Med. 2014;27(1):115–22.

49. Fischer-Rasmussen W, Kjær SK, Dahl C, Asping U. Ginger treatment of induced nausea: a randomised controlled trial. Acta Med Iran. 2009;47(1):51–6.

50. Smith C, Cowherter C, Willson K, Hornham M, McMillan V. A randomized controlled trial of ginger to treat nausea and vomiting in pregnancy. Obstet Gynecol. 2004;103(4):639–45.

51. Keating A, Chez RA. Ginger syrup as an antiemetic in early pregnancy. Altern Ther Health Med. 2002;8(5):89–91.

52. Basirat Z, Moghadamnia AA, Kashifard M, Sarifi-Razavi A. The effect of comparing the effects of ginger and dimenhydrinate in the treatment of nausea and vomiting in pregnant women. Pak J Biol Sci. 2009;47(1):51–6.

53. Wilberts KE, Ekangaki A, Eden JA. Effect of a ginger extract on pregnancy-induced nausea: a randomised controlled trial. J Obstet Gynecol Ind. 2010;6(2):14–6.

54. Mohammadbeigi R, Shahgeibi S, Soufizadeh N, Rezaiie M, Farhadifar F. Comparison of ginger and vitamin B6 in the treatment of nausea and vomiting of pregnancy. J Med Assoc Thai. 2003;86(9):846–53.

55. Haji Seid Javadi E, Salehi F, Mashrabi O. Comparing the effectiveness of vitamin b6 and ginger in treatment of pregnancy-induced nausea and vomiting. J Med Assoc Thai. 2011;94(10):1703–9.

56. Enishey J, Sakineh MA. Comparing ginger and vitamin B6 for the treatment of nausea and vomiting in pregnancy: a randomised controlled trial. Medsurg J. 2009;25(6):649–53.

57. Sripromote M, Lechklyananda N. A randomized comparison of ginger and vitamin B6 in the treatment of nausea and vomiting of pregnancy. J Med Assoc Thai. 2003;86(9):846–53.

58. Haji Seid Javadi E, Salehi F, Mashrabi O. Comparing the effectiveness of vitamin b6 and ginger in treatment of pregnancy-induced nausea and vomiting. J Med Assoc Thai. 2011;94(10):1703–9.

59. Ryan JL, Heckler CE, Roscoe JA, et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer. 2012;20(7):1479–89.

60. Zick SM, Djuric Z, Ruffin MT, et al. Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(8):1930–6.

61. Fahimi F, Khoobadaf K, Amini S, Nakhshi F, Salamzad J, Baniasadi S. Evaluating the effect of zingiber officinale on nausea and vomiting in patients receiving cisplatin based regimens. Iran J Pharm Res. 2011;10(2):379–84.

62. Manusirivithaya S, Sripromote M, Tangjitgamol S, et al. Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer. 2004;14(6):1063–9.

63. Paleaki Y, Saedat A, Sabehkar A, Hashemian F, Taghikhani M, Abolhasani E. Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial. Integr Can Ther. 2012;11(3):204–11.

64. Sontakke S, Thawani V, Naik MS. Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: a randomized, cross-over, double blind study. Ind J Pharm. 2003;35:32–6.

65. Pillai AK, Sharma KD, Gupta YK, Bakhshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving highly emetogenic chemotherapy. Pediatr Blood Cancer. 2011;56(2):234–8.

66. Arfeen Z, Owen H, Plummer JL, Ilsley AH, Sorby-Adams RA, Doecke CJ. A double-blind randomized controlled trial of ginger for the prevention of post-operative nausea and vomiting. Anaesth Intensive Care. 1995;23(4):449–52.

67. Srivastava KC. Isolation and effects of some ginger components on platelet aggregation and eosinoid biosynthesis. Prostaglandins Leukot Med. 1986; 25(2–3):167–9.

68. Jiang X, Williams KM, Liauw WS, et al. Effect of ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59(4):425–32.

69. Portnoi G, Chng L-A, Karimi-Tabesh L, Koren G, Tan MP, Einarson A. Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Am J Obstet Gynecol. 2003;189(5):1374–7.

70. Heitmann K, Nordeng H, Holst L. Safety of ginger use in pregnancy: results from a large population-based cohort study. Eur J Clin Pharmacol. 2013;69(2):269–77.